Design of the LEONORA Randomized Clinical Trial: Impact of Synbiotic Prophylaxis on Lower Gastrointestinal Symptoms Following Colorectal Cancer Surgery - Scorecard - MDSpire
Advertisement
Design of the LEONORA Randomized Clinical Trial: Impact of Synbiotic Prophylaxis on Lower Gastrointestinal Symptoms Following Colorectal Cancer Surgery
Clinical Scorecard: Design of the LEONORA Randomized Clinical Trial: Impact of Synbiotic Prophylaxis on Lower Gastrointestinal Symptoms Following Colorectal Cancer Surgery
At a Glance
Category
Detail
Condition
Colorectal Cancer Surgery
Key Mechanisms
Synbiotics improve gut microbiota composition and gastrointestinal function.
Target Population
Patients undergoing colorectal cancer surgery.
Care Setting
Multicenter clinical trial in Germany.
Key Highlights
LEONORA trial is the largest placebo-controlled RCT on synbiotics in CRC patients.
Intervention includes a diverse probiotic formulation and potent prebiotic.
Study aims to assess impact on gastrointestinal quality of life and postoperative complications.
Guideline-Based Recommendations
Diagnosis
Monitor gastrointestinal symptoms post-surgery in CRC patients.
Management
Administer synbiotics post-surgery to improve gut function and reduce complications.
Monitoring & Follow-up
Collect stool samples to assess microbiota changes.
Risks
Current literature indicates no increased risk of complications with probiotics.
Patient & Prescribing Data
Colorectal cancer patients post-surgery.
Daily administration of synbiotics for 12 weeks starting post-surgery.
Clinical Best Practices
Utilize multi-strain probiotics for enhanced efficacy.
Incorporate prebiotics to support probiotic function.
